| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443872 | European Journal of Cancer | 2013 | 10 Pages |
Abstract
In conclusion we found substantial preclinical evidence for cross-resistance between the taxanes docetaxel and cabazitaxel, and AR targeting agents abiraterone and enzalutamide. Since these compounds all interfere with AR-signalling, this strongly suggests a common mechanism of action, and thus a potential mechanism for cross-resistance in mCRPC.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
R.J. van Soest, M.E. van Royen, E.S. de Morrée, J.M. Moll, W. Teubel, E.A.C. Wiemer, R.H.J. Mathijssen, R. de Wit, W.M. van Weerden,